Radiation Oncology, Treatment Protocols
A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Eligible for screening study DCP 001
R0848 will close to accrual at 5 PM ET Friday, June 1, 2018, because it has reached its accrual target. Step 2 randomization will remain open. All patients registered to Step 1 by Friday, June 1, 2018 will proceed to the randomization step (Step 2). If patients are unable to be randomized, Step 2 will still be completed with the reason for no randomization being provided.